Investigational drug · Phase 3
INT230-6
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sarcoma,Soft Tissue.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "INT230-6"
First trial start
2024
Jun 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INT230-6", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcoma,Soft Tissue
Largest trials
Live from ClinicalTrials.gov: studies naming "INT230-6" as an intervention, largest first.
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Pivotal-lookingRecruiting
Intensity Therapeutics, Inc.Industry
NCT06263231 · 333 participants (planned) · Start Jun 28, 2024 · Primary completion Dec 2027
Drug: INT230-6; Eribulin and 2 more · For: Sarcoma,Soft Tissue
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 20 sites in all
Intensity Therapeutics, Inc.Industry
NCT03058289 · 111 participants · Start Feb 9, 2017 · Primary completion Feb 22, 2023
Drug: INT230-6; anti-PD-1 antibody and 1 more · For: Breast Cancer; Head and Neck Cancer; Squamous Cell Carcinoma and 8 more
Sites: Los Angeles, California; Newport Beach, California; Baltimore, Maryland · 8 sites in all
- INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast CancerStatus unknown
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04781725 · 90 participants (planned) · Start Mar 25, 2021 · Primary completion Mar 1, 2022
Drug: INT230-6 · For: Breast Cancer
Sites: Ottawa, Canada
Swiss Cancer InstituteAcademic, hospital or other
NCT06358573 · 61 participants (planned) · Start Oct 24, 2024 · Primary completion Oct 2028
Drug: INT230-6 · For: Triple-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer
Sites: Lyon, France; Aarau, Switzerland; Basel, Switzerland · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.
Thomas JS, Siu LL, Ingham M, et al. · EBioMedicine 2025
- Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas.
Navasardyan I, Lim SYA, Crompton JG · Crit Rev Oncog 2025
- Current status of intralesional agents in treatment of malignant melanoma.
Zawit M, Swami U, Awada H, et al. · Ann Transl Med 2021
- Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Bender LH, Abbate F, Walters IB · Int J Mol Sci 2020
- Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.
Bloom AC, Bender LH, Tiwary S, et al. · Oncoimmunology 2019
Also in development for Sarcoma,Soft Tissue
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- AdAPT-001Phase 21 trial
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.